Phathom Pharmaceuticals, Inc.
NASDAQ:PHATBiotechnology
Healthcare
$5.08 -2.45%
-$0.27 today
- Market cap
- $412.96M
- Beta
- 0.51
- P/E (TTM)
- -5.6
- EPS (TTM)
- -$1.92
52W Low $7.61High $18.31
Volume 1.03M
Average 1.21M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$166.78M
FY 2025 · Annual
Investing Cash Flow
-$229,000.00
FY 2025 · Annual
Financing Cash Flow
-$288,000.00
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (143.88M) | (197.72M) | (201.59M) | (334.33M) | (221.25M) |
| Depreciation & Amortization | 521K | 620K | 575K | 795K | 633K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 16.81M | 24.13M | 45.03M | 24.05M | 28.72M |
| Change in Working Capital | (27.32M) | 5.44M | (13.64M) | (15.3M) | (12.38M) |
| Accounts Receivables | 0 | 0 | (1.64M) | (37.16M) | (39.33M) |
| Inventory | 0 | 0 | (9.44M) | (6.14M) | (11.78M) |
| Accounts Payables | (9.79M) | 8.68M | 6.41M | 34.94M | 34.1M |
| Other Working Capital | (17.52M) | (3.24M) | (8.98M) | (6.93M) | 4.63M |
| Other Non-Cash Items | 5.41M | 21M | 32.06M | 58.01M | 37.5M |
| Operating Cash Flow | (148.46M) | (146.53M) | (137.58M) | (266.77M) | (166.78M) |
| Capital Expenditures | (328K) | (1.04M) | (1.63M) | (135K) | (229K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (328K) | (1.04M) | (1.63M) | (135K) | (229K) |
| Debt Repayment | 42.76M | 95.45M | 39.32M | 59.4M | 0 |
| Common Stock Issued | 0 | 24.6M | 155.46M | 121.78M | 1.64M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.94M | 0 | 172.8M | 1.6M | (1.93M) |
| Financing Cash Flow | 44.71M | 120.04M | 367.58M | 182.77M | (288K) |
| Effect of Forex Changes | 0 | (345K) | 0 | 0 | 0 |
| Net Change in Cash | (104.08M) | (27.87M) | 228.37M | (84.13M) | (167.29M) |
| Free Cash Flow | (148.79M) | (147.57M) | (139.21M) | (266.91M) | (166.78M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$221.2M
+ D&A$633.0K
+ Stock-Based Comp$28.7M
+ Deferred Tax$0
- Working Capital-$12.4M
+ Other Non-Cash$37.5M
= Operating Cash Flow-$166.8M
- Capex-$229.0K
= Free Cash Flow-$166.8M
Analysis
FY2025 free cash flow is -$166.8M. FCF conversion is 75.4% of net income. Operating cash flow was -$166.8M, with capex of -$229.0K. The largest bridge item is Other Non-Cash at $37.5M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 10, 2026 | |
| SC 13D/A | SC 13D/A filing | Nov 2, 2026 | |
| 10-Q | Quarterly report | Oct 29, 2026 | |
| 8-K | Current report | Oct 29, 2026 | |
| 8-K | Current report | Oct 26, 2026 |
Does PHAT generate free cash flow?
Phathom Pharmaceuticals, Inc. (PHAT) generated -$166.78M of free cash flow in fiscal 2025.
How much operating cash flow does PHAT produce?
Operating cash flow was -$166.78M, before capital expenditures of $229,000.00.
Continue the stock analysis
Jump to another research area for this company.